Abstract:Early on in the COVID-19 pandemic it was reported that angiotensin converting enzyme 2 inhibitors (ACE2i) could be associated with worse disease course due to potential increase in ACE2 receptors which SARS-CoV2 virus uses for cellular entry. Subsequent studies refuted such concerns, reporting that the continued use of ACEis and angiotensin receptor blockers (ARBs) in hypertensive individuals is in fact protective. Moreover, certain comorbidities, such as hypertension and heart disease, have been linked to an increased risk of disease severity. However, there is still paucity of data evaluating the effects of the use of different antihypertensive medications, steroids and beta blockers in chronic kidney disease (CKD) populations and in individuals with normal kidney function. This study was designed to evaluate the potential risk associated with renin angiotensin system inhibitors, calcium channel blocker, mineralocorticoid receptor blocker, steroids and beta blockers in a cohort of mostly African Americans and Caucasians. We conducted a retrospective study on patients who were admitted to the Detroit Medical Center, Detroit, MI during March and April of 2020. The data were collected through the medical chart reviews. We assessed 330 patients using inclusion criteria of age > 18 years and a positive SARS-CoV2 PCR test. We used the mean, standard deviation/standard error of mean, and percentages when appropriate for the description of patient characteristics. Group differences (CKD vs. non-CKD) were compared using the Pearson χ2 test. P-values of <0.05 were regarded as significant. We conducted binary logistic regression analysis to determine the effect of biological sex and CKD status on death due to COVID-19 during hospitalization. We conducted multivariate regression analysis for factors contributing to death during hospitalization due to COVID-19 and ICU admission, evaluating the contribution of different medications, comorbidities, and clinical course of the disease. On regression analyses, the odds of death in the hospital due to COVID-19 infection was not significantly associated with either biological sex or CKD status in our sample population. The odds of dying in the hospital were higher in patients who were on calcium channel blockers (OR 2.99, 95% CI 1.29-6.93, P = 0.01) and steroids (OR 4.23, 95% CI 1.17-15.31, P = 0.03). The only significance for ICU admission was obtained for steroid use (OR 1.872, 95% CI 1.059-3.311, P = 0.03). Likewise, COPD was the only comorbidity found to be associated with ICU admission (OR 2.38, 95% CI 1.282 - 4.426, P = 0.006), Significant associations were not observed for patients taking ACEis, ARBs, mineralocorticoid receptor inhibitors, diuretics, beta blockers and sympatholytics. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Admission systolic blood pressure and obesity correlate with fatal and severe acute COVID-19 in the population of New Orleans, LA.

Association Between Socio-demographic and Clinical Factors and Health Outcomes among COVID-19 Patients in a Community Hospital in Alabama

Obesity is Associated with Increased Severity of Disease in COVID-19 Pneumonia: a Systematic Review and Meta-Analysis

Obesity is Associated with Worse Outcomes in COVID‐19: Analysis of Early Data from New York City

The Association of Obesity, Type 2 Diabetes, and Hypertension with Severe Coronavirus Disease 2019 on Admission Among Mexican Patients

Association of hypertension with mortality in patients hospitalised with COVID-19

Clinical and laboratory characteristics of patients hospitalized with severe COVID-19 in New Orleans, August 2020 to September 2021

Initial mean arterial blood pressure (MABP) measurement is a risk factor for mortality in hypertensive COVID-19 positive hospitalized patients

Association Of Acei/Arb Use And Clinical Outcomes Of Covid-19 Patients With Hypertension

Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019

Blood Pressure Control and Adverse Outcomes of COVID-19 Infection in Patients with Concomitant Hypertension in Wuhan, China

Clinical characteristics and fatal outcomes of hypertension in patients with severe COVID-19

Obesity is Associated with Increased Risk for Mortality Among Hospitalized Patients with COVID‐19

Obesity is Associated with Severe Forms of COVID‐19

Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization

The effects of different antihypertensive medications, steroids and beta blocker on COVID-19 outcomes in a biracial CKD and non-CKD cohort

Clinical Course and Outcomes of COVID-19 Patients with Hypertension

Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City.

Mid-regional proadrenomedullin, C-terminal proendothelin-1 values, and disease course are not different in critically ill SARS-CoV-2 pneumonia patients with obesity

Association between hypertension and clinical outcomes in COVID-19 patients: a case-controlled study

Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study